United Therapeutics Co. (NASDAQ:UTHR) CFO Sells $2,794,367.04 in Stock

United Therapeutics Co. (NASDAQ:UTHR) CFO James Edgemond sold 7,792 shares of United Therapeutics stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $358.62, for a total transaction of $2,794,367.04. Following the completion of the transaction, the chief financial officer now directly owns 4,802 shares of the company’s stock, valued at $1,722,093.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

James Edgemond also recently made the following trade(s):

• On Monday, September 23rd, James Edgemond sold 7,796 shares of United Therapeutics stock. The shares were sold at an average price of $354.04, for a total transaction of $2,760,095.84.
• On Monday, September 9th, James Edgemond sold 7,802 shares of United Therapeutics stock. The shares were sold at an average price of $345.41, for a total value of $2,694,888.82.
• On Tuesday, September 3rd, James Edgemond sold 7,785 shares of United Therapeutics stock. The stock was sold at an average price of $362.37, for a total value of $2,821,050.45.

United Therapeutics Stock Performance

Shares of UTHR opened at $350.07 on Friday. The business has a 50-day simple moving average of $343.43 and a two-hundred day simple moving average of $298.16. The company has a quick ratio of 4.18, a current ratio of 4.35 and a debt-to-equity ratio of 0.02. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $366.08. The stock has a market cap of $15.53 billion, a price-to-earnings ratio of 16.55, a PEG ratio of 1.30 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.33 by ($0.48). The firm had revenue of $714.90 million during the quarter, compared to analysts’ expectations of $691.87 million. United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The company’s revenue was up 19.8% compared to the same quarter last year. During the same period in the prior year, the company posted $5.24 earnings per share. On average, analysts expect that United Therapeutics Co. will post 24.71 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 2nd. HC Wainwright reiterated a “buy” rating and issued a $400.00 price target on shares of United Therapeutics in a research note on Thursday, August 1st. UBS Group increased their price objective on shares of United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a research report on Monday, July 8th. TD Cowen lifted their target price on shares of United Therapeutics from $270.00 to $350.00 and gave the stock a “buy” rating in a research report on Thursday, July 11th. Finally, Morgan Stanley cut United Therapeutics from an “overweight” rating to an “equal weight” rating and increased their price target for the company from $310.00 to $321.00 in a report on Thursday, July 11th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $357.17.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC grew its holdings in United Therapeutics by 176.2% during the 1st quarter. SG Americas Securities LLC now owns 14,315 shares of the biotechnology company’s stock valued at $3,288,000 after buying an additional 9,133 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in United Therapeutics by 19.0% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 25,686 shares of the biotechnology company’s stock valued at $5,901,000 after acquiring an additional 4,100 shares in the last quarter. Comerica Bank increased its holdings in United Therapeutics by 5.9% in the 1st quarter. Comerica Bank now owns 165,911 shares of the biotechnology company’s stock valued at $38,113,000 after acquiring an additional 9,244 shares during the last quarter. Tri Locum Partners LP purchased a new stake in United Therapeutics in the 2nd quarter worth $15,959,000. Finally, QRG Capital Management Inc. boosted its holdings in shares of United Therapeutics by 12.4% during the 2nd quarter. QRG Capital Management Inc. now owns 15,321 shares of the biotechnology company’s stock valued at $4,880,000 after purchasing an additional 1,692 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.